Post by
Red~One on Mar 25, 2022 5:35pm
N.O. in the news, No Clas
GeNO recently completed a Phase 2 pilot study of its nitric oxide for use as a diagnostic in Pulmonary Arterial Hypertension (PAH), and the company is currently performing a dose-escalation trial for the Treatment of Pulmonary Hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF).
Comment by
PTBailey on Mar 29, 2022 9:08pm
Does this company still exist?
Comment by
PTBailey on Mar 30, 2022 9:07am
This is from an article posted August 9, 2012. GeNo article This study was completed in Sept of 2016, can you post link to results?